Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

U.S. stocks closed another record-setting week with a muted performance Friday, as hope built on Wall Street that the U.S. economy can manage the rare feat of suppressing high inflation without ...

The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...

The Dow Jones Industrial Average edged up to another record high while declines in tech stocks pulled other indexes lower.

The blue-chip Dow Jones Industrial Average closed at a record high as a subdued inflation report stoked hopes for more ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...

U.S. stock indexes are drifting around their records Friday as hopes hold that the economy can pull off the rare feat of ...

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...